Skip to main content

Table 1 Baseline characteristics of patients with HBV and HCV after exposure to ACEIs or ARBs within 6 months after the index date

From: Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in chemoprevention of hepatocellular carcinoma: a nationwide high-risk cohort study

 

HBV patients

 

HCV patients

Variables

All

Initial exposure

Initial non-exposure

 

All

Initial exposure

Initial non-exposure

n

7724

3575

4149

 

7873

3349

4524

Gender (male, %)

66.2

68.8*

63.9

 

49.3

51.8*

47.4

Mean age (years) (SD)

57.4 (11.3)

57.5 (11.2)

57.3 (11.5)

 

59.5 (9.1)

59.7 (9.3)

59.3 (9.0)

Liver cirrhosis (%)

78.9

77.8*

79.8

 

88.0

87.0*

88.7

Comorbidities

       

 DM (%)

36.6

43.8*

30.4

 

35.9

45.7*

28.6

 Hyperlipidemia (%)

40.3

45.6*

35.7

 

31.3

36.4*

27.6

 Other cancer (%)

24.8

21.1*

27.7

 

4.6

4.2

5.0

 COPD (%)

11.4

11.3

11.5

 

12.0

12.5

11.7

 End-stage renal disease (%)

1.7

1.7

1.6

 

1.2

1.3

1.2

 Transplant (%)

2.9

3.1

2.7

 

0.6

0.9*

0.3

 Alcohol use (%)

1.7

1.2*

2.2

 

0.7

0.4*

0.9

Mean follow up years (SD)

4.0 (1.7)

4.0 (1.6)

4.0 (1.7)

 

4.6 (1.5)

4.5 (1.4)

4.7 (1.5)

Last status

       

 HCC (n, %)

552 (7.1)

258 (7.2)

294 (7.1)

 

503 (6.4)

193 (5.8)

310 (6.9)

 Death (n, %)

1282 (16.6)

508 (14.2)

774 (18.7)

 

261 (3.3)

115 (3.4)

146 (3.2)

  1. DM diabetes mellitus, COPD chronic obstructive pulmonary disease, HCC hepatocellular carcinoma
  2. *p < 0.05 between initial exposure and non-exposure groups